This week’s Cholera outbreak in the UK is the latest example of the dangers posed by a surge in the global trade in pharmaceuticals.
The World Health Organisation (WHO) has warned that a surge of infections has reached a record-high level of 6.7 million cases in the first three weeks of the year.
But it also points to an opportunity for the UK and other countries to act.
Dr Tom Durnin, a senior lecturer at the University of East Anglia, says the country has a lot of work to do to improve the quality of its healthcare.
“The UK’s lack of access to healthcare services, especially for people in rural areas, has become a significant impediment to the delivery of critical healthcare services and the delivery to patients of healthcare services,” he says.
We need to look at the ways we can improve the infrastructure and the technology, he says, “but at the same time, we need to make sure we have the right services to provide those services.
This is a challenge for the NHS and we’re going to be facing it for some time.”
Cholera, a virus caused by a bacterium called Clostridium difficile, is transmitted through food, water and contaminated water.
It is the leading cause of diarrhoea in some developing countries and is transmitted to many more people than other major diseases such as pneumonia.
In the UK, the disease affects around 300,000 people and causes infections that can cause pneumonia, diarrhoeas, vomiting and severe fevers.
In March, a new coronavirus, C57, was discovered in England.
The new strain of the virus was found to be the most virulent in a period of time, causing more than 100,000 deaths.